Ocera Therapeutics (OCRX) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ocera Therapeutics Reports Second Quarter 2015 Financial Results
August 3, 2015 4:13 PM EDTContinued Strong Enrollment in STOP-HE
On Track for Initiation of Phase 1 Trial with Oral Formulation of OCR-002 in Third Quarter
$20 Million Debt Facility Extends Cash Resources to Mid-2017
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced recent business highlights and reported financial results for the quarter ended June 30, 2015.
I am pleased... More
Ocera Therapeutics Reports Second Quarter 2015 Financial Results
August 3, 2015 4:13 PM EDTContinued Strong Enrollment in STOP-HE
On Track for Initiation of Phase 1 Trial with Oral Formulation of OCR-002 in Third Quarter
$20 Million Debt Facility Extends Cash Resources to Mid-2017
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced recent business highlights and reported financial results for the quarter ended June 30, 2015.
I am pleased... More
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank
July 30, 2015 4:05 PM EDTPALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. Â (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it secured a $20 million debt facility from Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). Ocera intends to use the additional capital to support the ongoing development of the companys novel molecule OCR-002 to treat acute and chronic patients with hepatic encephalopathy.
This facility provides additional financial strength and flexibility at an attractive cost of capital with the... More
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank
July 30, 2015 4:05 PM EDTPALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. Â (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it secured a $20 million debt facility from Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). Ocera intends to use the additional capital to support the ongoing development of the companys novel molecule OCR-002 to treat acute and chronic patients with hepatic encephalopathy.
This facility provides additional financial strength and flexibility at an attractive cost of capital with the... More
